Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19 (oXAKI-COV)
Covid19, AKI
About this trial
This is an interventional treatment trial for Covid19 focused on measuring COVID-19, AKI, CRRT, AN69 Oxiris, AN69 Standar
Eligibility Criteria
Inclusion Criteria:
- Patients aged ≥ 18 years old.
- A diagnosis of a confirmed, defined by a positive rt-PCR for SARS CoV-2, or suspected COVID-19 disease, with suggestive findings on a chest CT scan.
- Patients on mechanical ventilation.
- The presence of an informed consent signed by the next of kin.
- Patients with KDIGO AKI stage 2: defined by a rise in creatinine 2-2.9 times baseline and/or a urinary output less than 0.5 ml/kg/hr for 12 hours, with failure after a furosemide stress test.
- The use of vasopressor, any dose.
- Complete medical history and complete laboratories.
Exclusion Criteria:
- Chronic kidney disease KDIGO stage 4, 5, or 5D.
- Next of kin unwilling or patient unwilling to participate.
- Patients with a life expectancy of fewer than 72 hours according to the attending physician criteria.
- Patients older than 75 years.
- Patients with SOFA > 11.
- Patients with severe liver failure.
Sites / Locations
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
AN69 Oxiris
AN69 Standard
To evaluate the safety in using the AN69-Oxiris membrane in contrast with the use of a conventional membrane in critically ill patients with COVID-19 associated AKI and CRRT requirements. To examine the efficacy of the AN69-Oxiris membrane in reducing inflammatory interleukins compared with reduction using conventional membranes in this specific group of patients. To exhibit the potential benefit of AN69-Oxiris in decreasing ICU length of stay versus the effect of using conventional membranes in COVID-19 associated AKI. To investigate the effect of AN69-Oxiris in reducing 28-day mortality in contrast compared with the effect of a conventional membrane in this population.
To evaluate the safety in using the AN69-Oxiris membrane in contrast with the use of a conventional membrane in critically ill patients with COVID-19 associated AKI and CRRT requirements. To examine the efficacy of the AN69-Oxiris membrane in reducing inflammatory interleukins compared with reduction using conventional membranes in this specific group of patients. To exhibit the potential benefit of AN69-Oxiris in decreasing ICU length of stay versus the effect of using conventional membranes in COVID-19 associated AKI. To investigate the effect of AN69-Oxiris in reducing 28-day mortality in contrast compared with the effect of a conventional membrane in this population.